Healthcare Swedish Community

1. The Narrative: The High Tech Precision Play The narrative for RaySearch is that of a highly specialized software leader in the oncology market.Read more

EQL Pharma is pushing hard to expand its range of everyday medicines, with a growing lineup of new products that could keep sales climbing fast. The catch is that the shares already reflect a lot of optimism, and execution plus cash flow need to keep up for the story to work.Read more

A small Swedish biotech is trying to make medicines work better and last longer in the body by wrapping them in a protective “shell.” The big question is whether this delivery tech can attract major partners and turn early promise into real products—before setbacks or slow adoption get in the way.Read more

Dedicare supplies health and social care staff in a region where ageing populations and ongoing staff shortages keep demand strong. The catch is that tougher rules and fiercer rivals are squeezing results, and the story hinges on whether Dedicare can defend its position while expanding into new markets.Read more

Europe’s aging population and a growing shift toward private healthcare could play right into Medicover’s hands, especially as it expands hospitals and higher-value diagnostic services. The catch is that big build-outs, rising staff costs, and changing rules in its key countries could quickly squeeze results if growth doesn’t keep pace.Read more

Sedana Medical is on the verge of a much bigger stage as it pushes into the U.S. while building momentum across Europe and widening use for children. The upside looks tied to whether hospitals adopt its ICU sedation approach and regulators sign off, but delays, competition, and rising costs could quickly change the story.Read more

Vimian aims to ride the global boom in pet ownership with new veterinary devices, specialty medicines, and digital tools that could make clinics lean on its products more often. The upside hinges on smoother demand after recent changes and a steady stream of new launches, but tariffs, a consumer pullback on optional pet care, and deal-making missteps could squeeze profits.Read more

EQL Pharma is pushing beyond the Nordics into bigger European markets while building out a long list of new generic medicines, aiming to turn a wider footprint into steadier growth. The upside hinges on smooth product approvals and supply chains, while heavy spending and tough, price-focused competition could quickly squeeze profits.Read more

Elekta’s newest software is gaining traction in Europe and its service business keeps growing, which could make revenue steadier as more hospitals upgrade to more precise cancer treatment tools. The big question is whether China rebounds as expected while tariffs, currency swings, approvals, and tougher competition keep pressure on profits.Read more